Akari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York City
September 16, 2016 12:18 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced that Dr. Gur Roshwalb, Chief...
Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
July 13, 2016 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK...
Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir for the Treatment of Genotype 1 Chronic HCV
October 16, 2015 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen)...
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
September 22, 2015 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...
C3 Jian Completes Second Phase 2 Clinical Trial of Anti-Cavity Drug
July 13, 2015 06:00 ET
|
C3 Jian, Inc.
LOS ANGELES, July 13, 2015 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a biotechnology company focused on reengineering the human microbiome to deliver novel healthcare products, announced it has preliminary...
C3 Jian Completes Phase 2 Clinical Trial of Anti-Cavity Drug
September 09, 2014 06:00 ET
|
C3 Jian, Inc.
LOS ANGELES, Sept. 9, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that it has successfully completed the initial Phase 2...
Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
March 12, 2014 12:58 ET
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, March 12, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its...
C3 Jian Initiates Phase 2 Clinical Trial of Anti-Cavity Drug
March 07, 2014 18:40 ET
|
C3 Jian, Inc.
LOS ANGELES, March 7, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that the first Phase 2 Clinical Trial for its novel drug,...
Aquinox Pharmaceuticals Prices Initial Public Offering
March 07, 2014 09:00 ET
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a...
Study Shows Weight Loss and Decreased Food Cravings With Phase 2 White Kidney Bean Extract
December 03, 2013 12:02 ET
|
Phase 2
KEARNY, NJ--(Marketwired - Dec 3, 2013) - Obesity, the official peer-reviewed research journal of The Obesity Society, has published the largest weight loss and weight management clinical study, to...